SOLODYN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLODYN (SOLODYN).
Solodyn (minocycline hydrochloride) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
| Metabolism | Minocycline is metabolized in the liver via oxidative pathways, producing multiple metabolites including 9-hydroxyminocycline and 8-hydroxyminocycline. Enzymes involved include CYP450 isozymes, though specific isozymes are not well characterized. |
| Excretion | Primarily renal (40-70% unchanged) via glomerular filtration; significant biliary/fecal (20-30%) as unchanged drug and metabolites. Enterohepatic recirculation occurs. |
| Half-life | Terminal elimination half-life: 11-22 hours (mean ~16 hours). Clinically, steady-state reached in 3-4 days; half-life prolonged in renal impairment. |
| Protein binding | 75-80% bound primarily to serum albumin. |
| Volume of Distribution | 0.7-1.5 L/kg; extensive tissue distribution including bone, liver, and tumor tissues. |
| Bioavailability | Oral: 90-100% (immediate-release); reduced to 75-85% with food (but food decreases nausea). Extended-release (Solodyn) has 100% relative bioavailability compared to immediate-release. |
| Onset of Action | Oral: 1-2 hours for detectable serum levels; clinical effects (anti-inflammatory) may take 2-4 weeks for rosacea. |
| Duration of Action | Therapeutic effects persist for 24 hours after oral dosing, supporting once-daily regimen; anti-inflammatory effects may continue for weeks after discontinuation. |
1 mg/kg orally once daily as extended-release tablets; not to exceed 100 mg/day. Alternatively, 1 mg/kg orally once daily as immediate-release tablets; not to exceed 100 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For severe renal impairment (CrCl <30 mL/min), administer 50% of usual dose or consider alternative therapy. |
| Liver impairment | No specific dose adjustment recommended in mild to moderate hepatic impairment; use caution in severe hepatic impairment (Child-Pugh class C). |
| Pediatric use | For children 12 years and older: 1 mg/kg orally once daily as extended-release tablets, not to exceed 100 mg/day. For children under 12 years: not FDA approved for this age group. |
| Geriatric use | In elderly patients, no specific dose adjustment recommended; monitor for renal function and potential increased adverse effects (e.g., photosensitivity, gastrointestinal disturbances). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOLODYN (SOLODYN).
| Breastfeeding | Distributed into breast milk with M/P ratio 0.6-1.5. Avoid or discontinue nursing due to risk of dental discoloration and skeletal growth inhibition in infant. |
| Teratogenic Risk | Category D. Tetracyclines cause fetal harm (retarded skeletal development, dental discoloration, enamel hypoplasia). Avoid in second and third trimesters. Use only if no alternative. |
| Fetal Monitoring |
■ FDA Black Box Warning
None FDA boxed warning specific to Solodyn. However, tetracycline-class antibiotics have a class warning regarding photosensitivity and should be used with caution in patients with hepatic or renal impairment.
| Serious Effects |
["Hypersensitivity to minocycline, any tetracycline, or any component of the formulation.","Concomitant use with isotretinoin (risk of pseudotumor cerebri).","Use in pregnancy (category D) and in children under 12 years of age due to permanent tooth discoloration and bone growth inhibition."]
| Precautions | ["Photosensitivity: exaggerated sunburn reaction; avoid sunlight or tanning beds.","Hepatotoxicity: rare but serious; discontinue if signs of liver injury occur.","Pseudotumor cerebri (intracranial hypertension): headache, blurred vision, papilledema.","Drug-induced lupus and autoimmune syndromes.","Superinfection: use of antibiotics may result in overgrowth of nonsusceptible organisms, including fungi.","Use with caution in patients with renal impairment as minocycline is excreted renally.","Contains FD&C Yellow No. 6 (tartrazine) which may cause allergic reactions in susceptible individuals."] |
Loading safety data…
| Monitor maternal liver function, renal function, and complete blood count. Assess fetal growth and development via ultrasound if exposure occurs in second/third trimester. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment at therapeutic doses. |